Covid19NCT04595240
Semen Analysis Changes in Covid-19 Positivepatients
An observational study of Covid19, run by Assiut University at 1 site in Egypt.
Trial summary
The viral pandemic of the coronavirus disease 2019 (COVID-19), generated by a novel mutated severe acute respiratory syndrome coronavirus (SARS-CoV-2), has become a serious worldwide public health emergency, evolving exponentially. Read more about this study
- Who is it for?
- Ages 20 to 45 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Covid19
- What is being tested?
- semen analysis
- How many people
- 100 participants
- Where
- 1 siteEgypt
- Study dates
- 1 May 2020to 15 Oct 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 45 years
- Men only
- Healthy volunteers accepted
- Adult
Study population: men with th mentioned criteria
Who may be able to join
- adult male patient age younger than 45 years old
- no history of fertility disorders
- good body built and secondary sexual charcter .
Who cannot join
- congenital anomalies of the testis
- chronically ill patients
- proplems of male fertility
- males with varicocele
- sexual performance disorders .
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Semen Analysis Changes in Covid-19 Positive Patients
The viral pandemic of the coronavirus disease 2019 (COVID-19), generated by a novel mutated severe acute respiratory syndrome coronavirus (SARS-CoV-2), has become a serious worldwide public health emergency, evolving exponentially. While the main organ targeted in this disease is the lungs, other vital organs, such as the heart and kidney, may be implicated. The main host receptor of the SARS-CoV-2 is angiotensin converting enzyme 2 (ACE2), a major component of the renin-angiotensin-aldosterone system (RAAS). The ACE2 is also involved in testicular male regulation of steroidogenesis and spermatogenesis. As the SARS-CoV-2 may have the potential to infect the testis via ACE2 and adversely affect male reproductive system.
Read the detailed description
A recent report published in JAMA Network Open revealed that in an analysis 38 semen samples from COVID-19 patients, 6 (four at the acute stage of infection and, alarmingly, two who were recovering) tested positive for the virus by RT-PCR.
Importantly, at this point, the investigators have no idea whether the actual virus was viable and infectious. Nevertheless, the possibility that this coronavirus could have a pathophysiological impact on the testes was suggested by additional data indicating that active COVID-19 infection dramatically reduced the testosterone-to-LH ratio, suggesting a significant impact on the responsiveness of Leydig cells to LH stimulation In many ways, the investigators should not be surprised by these observations because the blood-testes barrier is known to offer little defense against viral invasion, given the wide range of pathogenic viruses (HIV, hepatitis, mumps, papilloma) that are known to be capable of damaging the testes and rendering the host infertile.
The angiotensin system plays a critical role in the survival and functionality of human spermatozoa but also creates a vulnerability to COVID-19 attack. Angiotensin 1 is a biologically inactive decapeptide that is cleaved by ACE1 to create angiotensin II, which in turn activates the AT1R and AG2R receptors, both of which are present in these cells. Angiotensin II is further processed by ACE2 to generate angiotensin 1-7 which binds the MAS receptor activating PI3K. The latter then phosphorylates AKT, which maintains cell viability by phosphorylating key regulators of sperm apoptosis such as BAD. As long as BAD is phosphorylated, it is held in abeyance by a 14-3-3 keeper protein. However, if the PI3/AKT pathway becomes compromised, BAD dephosphorylates, is released from its association with 14-3-3, and moves to the mitochondria where it inactivates anti-apoptotic factors and promotes the intrinsic apoptotic cascade. The spike protein on COVID-19 specifically targets ACE2 and in so doing removes an important stimulus for PI3K/AKT, thereby compromising sperm viability. Subsequent to COVID-19 binding, the ectodomain of ACE2 may be removed by ADAM proteases and shed from the sperm surface. Alternatively proteases from the TMPRSS-family, either as intrinsic components of the sperm plasma membrane or delivered by seminal prostasomes, can facilitate fusion between the virus and the sperm surface by cleaving ACE2 and the viral spike proteins (S1 and S2) at the sites indicated by dashed lines, thereby completing the transformation of this cell from procreating gamete to viral vector.
An additional concern of the COVID-19 pandemic that might impact male fertility is fever. Particularly high and sustained elevation in body temperature is a major manifestation of the COVID-19 pandemic, which complicates more than 80% of patients. The concept that fever and elevation of testicular temperature result in impairment of spermatogenesis is widely accepted.
More importantly, emerging evidence indicates that a subgroup of patients with severe COVID-19 might have a secondary cytokine storm syndrome (hemophagocytic lymphohistiocytosis). This is an underrecognized, hyperinflammatory syndrome characterized by sustained fever, with fulminant and fatal hypercytokinemia with multiorgan failure. These patients have a particular serum blood cytokine profile with cytopenia and hyperferritinemia. These findings also suggest that immunomodulatory therapy (IL-6 antagonist) may improve mortality rate considerably in these patients.
As cytokines contribute to testicular function and maintenance of male reproductive health, and to the pathologies associated with their abnormal activity in this organ, COVID-19-induced changes in cytokines profile may have further implications to male fertility. In addition, immunomodulatory therapies may provoke potential long-term effects on male fertility and are a matter of concern. Furthermore, cytokine microenvironment deviations within the testis may have tumorigenic adverse effects on the cellular level, leading eventually to testicular cancer, a second long-term matter of concern.
Aim of the study :
Know the Effect of covid-19 on spermatogenesis
- Conditions
- Covid19
- Being tested
- semen analysis
- Medical subject headings
- COVID-19
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
semen analysisDiagnostic test
semen analysis
What is being measured
The primary outcome is the main question the study is designed to answer.
changes of semen volume in (ML)by covid-19 from normal values.
semen analysis taken by 72day of infection to see the effect on the new cycle of spermatogenesis
Measured: 72days after infection
changes of sperm concentration in (million/ml) by covid-19 from normal values.
semen analysis taken by 72day of infection to see the effect on the new cycle of spermatogenesis
Measured: 72days after infection
changes of sperm morphology in (percentage of normal forms) by covid-19 from normal values.
semen analysis taken by 72day of infection to see the effect on the new cycle of spermatogenesis
Measured: 72days after infection
changes of sperm motility in percentage of (A+B) by covid-19 from normal values.
semen analysis taken by 72day of infection to see the effect on the new cycle of spermatogenesis
Measured: 72days after infection
changes of semen volume in (ML) by covid-19 from from the first sample
semen analysis taken by 72day of the first negative swab of covid-19 to see the effect on the new cycle of spermatogenesisand to compare with the first sample which done during infection.
Measured: after 72 days of the first sample
changes of sperm concentration in (million /ML) by covid-19 from from the first sample
semen analysis taken by 72day of the first negative swab of covid-19 to see the effect on the new cycle of spermatogenesisand to compare with the first sample which done during infection.
Measured: after 72 days of the first sample
changes of sperm morphology in percentage of normal form by covid-19 from from the first sample
semen analysis taken by 72day of the first negative swab of covid-19 to see the effect on the new cycle of spermatogenesisand to compare with the first sample which done during infection.
Measured: after 72 days of the first sample
changes of sperm motility in percentage of (A+B) by covid-19 from from the first sample
semen analysis taken by 72day of the first negative swab of covid-19 to see the effect on the new cycle of spermatogenesisand to compare with the first sample which done during infection.
Measured: after 72 days of the first sample
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Oct 2020
- Study start1 May 2020
- Primary completion15 Oct 2020
- Study completion15 Oct 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Covid19Studies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 100 participants (actual)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, mostafa kamel abdel rahman abdel aal, Assiut University
- Investigators
- ahmed a abdel moniem, md, Study director, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04595240
- Sponsor's protocol ID
- Semen analysis post covid-19
- Status last verified
- Oct 2020
- First submitted
- 14 Oct 2020
- Last updated
- 20 Oct 2020
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Mohammed N, Kamel M, Gadelkareem RA, Zarzour MA, Kurkar A, Abdel-Moniem AM, Behnsawy H. Semen quality changes during infection and recovery phases of mild-to-moderate COVID-19 in reproductive-aged patients: a prospective case series. Basic Clin Androl. 2023 Jan 19;33(1):2. doi: 10.1186/s12610-022-00175-7.
PubMed 36653786
Study at a glance
From the registry record, last updated by the sponsor on 20 Oct 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Semen Analysis Changes in Covid-19 Positive Patients
- ClinicalTrials.gov ID
- NCT04595240
- Acronym / sponsor ID
- Semen analysis post covid-19
- Conditions
- Covid19
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 100 participants (actual)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 1 May 2020 (actual)
- Primary completion
- 15 Oct 2020 (actual)
- Study completion
- 15 Oct 2020 (actual)
- First posted
- 20 Oct 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The viral pandemic of the coronavirus disease 2019 (COVID-19), generated by a novel mutated severe acute respiratory syndrome coronavirus (SARS-CoV-2), has become a serious worldwide public health emergency, evolving exponentially. While the main organ targeted in this disease is the lungs, other vital organs, such as the heart and kidney, may be implicated. The main host receptor of the SARS-CoV-2 is angiotensin converting enzyme 2 (ACE2), a major component of the renin-angiotensin-aldosterone system (RAAS). The ACE2 is also involved in testicular male regulation of steroidogenesis and spermatogenesis. As the SARS-CoV-2 may have the potential to infect the testis via ACE2 and adversely affect male reproductive system.
Detailed description
A recent report published in JAMA Network Open revealed that in an analysis 38 semen samples from COVID-19 patients, 6 (four at the acute stage of infection and, alarmingly, two who were recovering) tested positive for the virus by RT-PCR.
Importantly, at this point, the investigators have no idea whether the actual virus was viable and infectious. Nevertheless, the possibility that this coronavirus could have a pathophysiological impact on the testes was suggested by additional data indicating that active COVID-19 infection dramatically reduced the testosterone-to-LH ratio, suggesting a significant impact on the responsiveness of Leydig cells to LH stimulation In many ways, the investigators should not be surprised by these observations because the blood-testes barrier is known to offer little defense against viral invasion, given the wide range of pathogenic viruses (HIV, hepatitis, mumps, papilloma) that are known to be capable of damaging the testes and rendering the host infertile.
The angiotensin system plays a critical role in the survival and functionality of human spermatozoa but also creates a vulnerability to COVID-19 attack. Angiotensin 1 is a biologically inactive decapeptide that is cleaved by ACE1 to create angiotensin II, which in turn activates the AT1R and AG2R receptors, both of which are present in these cells. Angiotensin II is further processed by ACE2 to generate angiotensin 1-7 which binds the MAS receptor activating PI3K. The latter then phosphorylates AKT, which maintains cell viability by phosphorylating key regulators of sperm apoptosis such as BAD. As long as BAD is phosphorylated, it is held in abeyance by a 14-3-3 keeper protein. However, if the PI3/AKT pathway becomes compromised, BAD dephosphorylates, is released from its association with 14-3-3, and moves to the mitochondria where it inactivates anti-apoptotic factors and promotes the intrinsic apoptotic cascade. The spike protein on COVID-19 specifically targets ACE2 and in so doing removes an important stimulus for PI3K/AKT, thereby compromising sperm viability. Subsequent to COVID-19 binding, the ectodomain of ACE2 may be removed by ADAM proteases and shed from the sperm surface. Alternatively proteases from the TMPRSS-family, either as intrinsic components of the sperm plasma membrane or delivered by seminal prostasomes, can facilitate fusion between the virus and the sperm surface by cleaving ACE2 and the viral spike proteins (S1 and S2) at the sites indicated by dashed lines, thereby completing the transformation of this cell from procreating gamete to viral vector.
An additional concern of the COVID-19 pandemic that might impact male fertility is fever. Particularly high and sustained elevation in body temperature is a major manifestation of the COVID-19 pandemic, which complicates more than 80% of patients. The concept that fever and elevation of testicular temperature result in impairment of spermatogenesis is widely accepted.
More importantly, emerging evidence indicates that a subgroup of patients with severe COVID-19 might have a secondary cytokine storm syndrome (hemophagocytic lymphohistiocytosis). This is an underrecognized, hyperinflammatory syndrome characterized by sustained fever, with fulminant and fatal hypercytokinemia with multiorgan failure. These patients have a particular serum blood cytokine profile with cytopenia and hyperferritinemia. These findings also suggest that immunomodulatory therapy (IL-6 antagonist) may improve mortality rate considerably in these patients.
As cytokines contribute to testicular function and maintenance of male reproductive health, and to the pathologies associated with their abnormal activity in this organ, COVID-19-induced changes in cytokines profile may have further implications to male fertility. In addition, immunomodulatory therapies may provoke potential long-term effects on male fertility and are a matter of concern. Furthermore, cytokine microenvironment deviations within the testis may have tumorigenic adverse effects on the cellular level, leading eventually to testicular cancer, a second long-term matter of concern.
Aim of the study :
Know the Effect of covid-19 on spermatogenesis
Study design
- Observational model
- Other
- Time perspective
- Prospective
Who may qualify
- Ages
- 20 to 45 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- men with th mentioned criteria
Key inclusion criteria (3 listed)
- adult male patient age younger than 45 years old
- no history of fertility disorders
- good body built and secondary sexual charcter .
Key exclusion criteria (5 listed)
- congenital anomalies of the testis
- chronically ill patients
- proplems of male fertility
- males with varicocele
- sexual performance disorders .
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| semen analysissemen analysis | Diagnostic test | – |
Primary outcome
changes of semen volume in (ML)by covid-19 from normal values.
Time frame: 72days after infection
semen analysis taken by 72day of infection to see the effect on the new cycle of spermatogenesis
changes of sperm concentration in (million/ml) by covid-19 from normal values.
Time frame: 72days after infection
semen analysis taken by 72day of infection to see the effect on the new cycle of spermatogenesis
changes of sperm morphology in (percentage of normal forms) by covid-19 from normal values.
Time frame: 72days after infection
semen analysis taken by 72day of infection to see the effect on the new cycle of spermatogenesis
changes of sperm motility in percentage of (A+B) by covid-19 from normal values.
Time frame: 72days after infection
semen analysis taken by 72day of infection to see the effect on the new cycle of spermatogenesis
changes of semen volume in (ML) by covid-19 from from the first sample
Time frame: after 72 days of the first sample
semen analysis taken by 72day of the first negative swab of covid-19 to see the effect on the new cycle of spermatogenesisand to compare with the first sample which done during infection.
changes of sperm concentration in (million /ML) by covid-19 from from the first sample
Time frame: after 72 days of the first sample
semen analysis taken by 72day of the first negative swab of covid-19 to see the effect on the new cycle of spermatogenesisand to compare with the first sample which done during infection.
changes of sperm morphology in percentage of normal form by covid-19 from from the first sample
Time frame: after 72 days of the first sample
semen analysis taken by 72day of the first negative swab of covid-19 to see the effect on the new cycle of spermatogenesisand to compare with the first sample which done during infection.
changes of sperm motility in percentage of (A+B) by covid-19 from from the first sample
Time frame: after 72 days of the first sample
semen analysis taken by 72day of the first negative swab of covid-19 to see the effect on the new cycle of spermatogenesisand to compare with the first sample which done during infection.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Oct 2020.
- Derived from this study: PubMed 36653786Mohammed N, Kamel M, Gadelkareem RA, Zarzour MA, Kurkar A, Abdel-Moniem AM, Behnsawy H. Semen quality changes during infection and recovery phases of mild-to-moderate COVID-19 in reproductive-aged patients: a prospective case series. Basic Clin Androl. 2023 Jan 19;33(1):2. doi: 10.1186/s12610-022-00175-7.
Related trials for Covid19
RecruitingPhase 2
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of Age
SARS-CoV-2
RecruitingObservational study
Viral Infections in Healthy and Immunocompromised Hosts
Anogenital Herpes, COVID-19
Active, not recruiting
Long COVID Brain Fog: Cognitive Rehabilitation Trial
Long COVID, Brain Fog
Recruiting
RSV Burden in Outpatient and Hospital Settings
RSV Infection, Children, Only
Active, not recruitingObservational study
Korean Post Marketing Surveillance for Comirnaty Injection (Bretovameran)
COVID-19 Vaccination
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
ahmed a abdel moniem, md study director
Assiut University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Covid19, run by Assiut University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 Oct 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
changes of semen volume in (ML)by covid-19 from normal values. (time frame: 72days after infection). The study lists 8 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04595240, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Oct 2020.